Totaligent, Inc. Announces Material Definitive Agreement With Ivan Klarich: Major Milestone Equity Plan and JV Launch

Totaligent, Inc. (OTC: TGNT), a publicly traded Delaware corporation specializing in intelligent business marketing, AI-powered data solutions, and strategic acquisitions, has announced the signing and closing of a Material Definitive Agreement with Ivan Klarich. This agreement is set to drive major corporate developments, including the formation of new joint ventures, milestone-based equity issuance, and operational restructuring.

Key Points in the Report

• Material Definitive Agreement Signed: Totaligent, Inc. and Ivan Klarich have entered into a legally binding agreement covering the formation of a new entity (Aetherium) and the launch of a major joint venture (GloMed) focused on medical solutions.
• Milestone-Based Equity Issuance: Klarich will be issued up to 38.26% of Totaligent’s fully diluted capitalization, subject to achieving specific performance milestones. Equity will be issued in the form of Series D Preferred Stock (convertible 1:1,000 into Common Stock) or as Common Stock, at the Company’s election.
• Milestone Schedule and Triggers:
  • 10% equity upon closing of the definitive agreement
  • +8% equity for launching the GloMed Joint Venture
  • +8% equity for achieving strategic partner alliances
  • +9% equity for reaching a \$3 million revenue run-rate
  • +9% equity for closing the Don Heath acquisition/transaction
  • Final adjustment to 38.26% upon successful uplist or qualified IPO
• Pro-Rata Issuance: If milestones are only partially achieved, Klarich will receive equity proportionate to the level of achievement.
• Board Determination: The Board of Directors will make good-faith determinations on milestone achievement, with binding arbitration available for disputes.
• No Anti-Dilution Protection: Future equity issuances may dilute Klarich’s ownership; there are no anti-dilution protections.
• SEC Compliance and Registration Path: All milestone equity is intended to be registered via Form S-1 or a resale shelf registration. Totaligent will file a Form 8-K and include these issuances in its registration statements.
• Tax Treatment Intent: Parties intend to structure milestone equity to potentially qualify for Qualified Small Business Stock (QSBS) treatment under Section 1202 of the Internal Revenue Code.
• Corporate Governance Controls: Totaligent will retain effective control of the new JV entity, including majority board seats, tie-breaker authority, and removal rights for cause.
• Capitalization Table:
  • Common Stock: 213,601,313 shares outstanding as of April 10, 2026
  • Series D Preferred Stock: 576,562 shares, convertible to 576,562,000 Common Stock
  • Convertible Notes: ~\$911,335 net book value, representing additional common stock equivalents
  • Total Fully Diluted Shares: 878,177,955
  • No outstanding options, warrants, or other dilutive securities
• Financial Condition: The Company has significant net losses, limited revenue, a stockholders’ deficit, and substantial doubt about its ability to continue as a going concern.
• Governance, Restrictions, and Indemnifications: Several restrictions are placed on the Company’s actions prior to closing, including restrictions on new debt, capital expenditures, acquisitions, and equity issuances not related to the agreement. Indemnification provisions are included for both parties.

Important Shareholder Information & Price-Sensitive Details

• Potential Dilution: The planned equity issuances to Klarich could significantly dilute existing shareholders, especially if all milestones are met. This is a major price-sensitive event.
• Uplist/IPO Target: The agreement includes a milestone for successful uplisting or IPO, which could materially enhance the Company’s profile and market valuation, but also triggers a large equity issuance to Klarich.
• JV Launch and Acquisition Strategy: Launching the GloMed Joint Venture and closing the Don Heath transaction could represent substantial growth opportunities, but also introduce execution and integration risks.
• Financial Concerns: The Company’s ongoing losses, negative cash flows, and going concern risk may impact valuation and investor sentiment.
• Board and Shareholder Approvals: Some equity issuances may require Board and (potentially) shareholder approval, which could affect timing and certainty of the transactions.
• Tax Structure: The effort to qualify for QSBS treatment may influence the attractiveness of the milestone shares to recipients, but is not guaranteed.
• No Anti-Dilution Protection: Shareholders should note Klarich does not receive anti-dilution protection, meaning future financing rounds or issuances could further dilute all shareholders.
• SEC Compliance: All new equity issuances are intended to be registered, increasing transparency but also possibly affecting trading liquidity.

Milestone Equity Issuance Schedule (For Ivan Klarich)

Additional Details

• Equity issuance is calculated on a fully diluted basis, immediately following each milestone achievement.
• If milestones are partially achieved, equity is issued pro-rata based on the percentage of achievement.
• Final ownership percentage is adjusted upon uplist or IPO to match the post-uplist target.
• All milestone shares issued are “restricted securities” under Rule 144 and subject to transfer restrictions.
• Board approval is required for milestone achievement; disputes are resolved by binding arbitration.
• Employment agreements, JV agreements, and disclosure schedules are part of the definitive package.
• The capitalization table does not reflect post-agreement issuances, conversions, or the impact of the Aetherium transaction or GloMed JV.
• No outstanding litigation, material undisclosed liabilities, or broker fees disclosed in the agreement.
• Company is a voluntary SEC filer, with historical delays and losses, but is executing a major turnaround strategy.

Potential Implications for Shareholders

• Significant Dilution Risk: The issuance of up to 38.26% of fully diluted shares to Klarich could materially dilute existing shareholders if all milestones are met. This is a price-sensitive event that may impact share value.
• Strategic Growth and Uplist Potential: The agreement includes aggressive targets for JV launches, revenue growth, acquisitions, and a public market uplisting, which may be positive for long-term valuation if executed successfully.
• Operational and Execution Risks: The Company’s financial challenges, including going concern doubts, mean there is significant risk in achieving the milestones and realizing shareholder value from these initiatives.
• Transparency and SEC Compliance: Registration of milestone equity and SEC filings may increase transparency and liquidity, but also highlight ongoing financial risks.

Disclaimer

Disclaimer: The information above is a summary based on Totaligent, Inc.’s Form 8-K and Material Definitive Agreement filed with the SEC. It is intended for informational purposes only and should not be construed as investment advice. Actual results may differ materially due to risks, uncertainties, and execution challenges. Investors should conduct their own due diligence and consult their financial advisors before making any investment decisions. The Company’s financial condition, operational risks, and dilution potential should be carefully considered.

View Totaligent, Inc. Historical chart here